Powder: -20°C for 3 years | In solvent: -80°C for 1 year
XRK3F2 is an inhibitor of the p62-ZZ domain, blunts MM-induced Runx2 suppression in vitro, and induces new bone formation and remodeling in the presence of tumor in vivo.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 34.00 | |
5 mg | In stock | $ 79.00 | |
10 mg | In stock | $ 122.00 | |
25 mg | In stock | $ 236.00 | |
50 mg | In stock | $ 372.00 | |
100 mg | In stock | $ 559.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 89.00 |
Description | XRK3F2 is an inhibitor of the p62-ZZ domain, blunts MM-induced Runx2 suppression in vitro, and induces new bone formation and remodeling in the presence of tumor in vivo. |
In vitro | XRK3F2 inhibits p62-ZZ domain signaling and rescues Myeloma-induced Gfi1-driven epigenetic repression of the Runx2 gene in pre-osteoblasts to overcome differentiation suppression. XRK3F2 prevents MM-induced upregulation of Gfi1 and repression of the Runx2 gene when present in MM-preOB co-cultures. p62-ZZ-domain blocking by XRK3F2 prevents MM conditioned media and TNF plus IL7-mediated Gfi1 mRNA upregulation and the concomitant Runx2 repression. XRK3F2 decreased MM-induced GFI1 occupancy at the Runx2-P1 promoter and prevented recruitment of HDAC1, thus preserving the transcriptionally permissive chromatin mark H3K9ac on Runx2 and allowing osteogenic differentiation[1]. |
Molecular Weight | 435.89 |
Formula | C23H24ClF2NO3 |
CAS No. | 2375193-43-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 135.0 mg/mL (309.7 mM), Sonication is recommended.
H2O: 0.8 mg/mL (1.9 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
XRK3F2 2375193-43-2 Autophagy XRK-3F2 inhibitor inhibit